Imatinib Immunoassay Antibodies Specific Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a simple and effective immunoassay for determining the presence and quantifying imatinib and its pharmacologically active salts in human biological fluids, due to cross-reactivity with its active metabolite N-desmethyl imatinib, which hinders accurate drug monitoring and dosage adjustment in cancer treatment.
Innovation Solution
Development of a new class of antibodies specifically reactive to imatinib and its pharmacologically active salts, produced using immunogens with reactive thiol or amino functional groups, which do not substantially react with N-desmethyl imatinib, enabling the creation of an immunoassay for precise detection and quantification in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional immunoassay methods are used to detect imatinib, then the assay can be performed with standard laboratory equipment, but the measurement precision is compromised due to cross-reactivity with N-desmethyl imatinib metabolite
Solution Approach 1:
The patent applies local quality by modifying specific regions of the imatinib molecule to create immunogen derivatives with enhanced specificity. By conjugating imatinib to carrier proteins through specific functional groups (such as amino or carboxyl groups) and using specific immunization protocols, the resulting antibodies exhibit localized binding specificity that distinguishes imatinib from its N-desmethyl metabolite, thereby resolving the cross-reactivity issue while maintaining measurement precision
Solution Approach 2:
The patent employs parameter changes by altering the chemical structure of imatinib through derivatization to create immunogens with modified properties. By changing parameters such as the conjugation site, carrier protein type, and immunization regimen, the resulting antibodies achieve enhanced specificity for imatinib over N-desmethyl imatinib, resolving the cross-reactivity problem while enabling accurate detection with standard laboratory equipment
2Measurement precision
If LC-tandem mass spectrometry is used to determine imatinib concentration, then measurement precision is improved, but the device complexity and cost increase significantly
Solution Approach 1:
The patent applies the copying principle by creating antibody-based detection systems that replicate the high specificity of mass spectrometry using simpler immunological reactions. The developed immunoassay uses antibody-antigen binding interactions to achieve concentration determination accuracy comparable to LC-MS/MS, but with the simplicity and accessibility of standard laboratory immunoassay equipment, thereby reducing device complexity while maintaining measurement precision
Solution Approach 2:
The patent substitutes the complex mechanical and chemical separation system of LC-MS/MS with a simpler immunological recognition system. By replacing the need for liquid chromatography columns, mass spectrometers, and complex sample preparation protocols with antibody-based detection, the invention achieves comparable measurement precision using significantly simpler equipment that is accessible in routine clinical laboratories
3Reliability
If imatinib dosage is increased to improve efficacy, then treatment effectiveness improves, but toxicity increases due to pharmacokinetic variability
Solution Approach 1:
The patent applies feedback by enabling routine monitoring of imatinib trough concentrations through a simple, specific immunoassay. This allows clinicians to measure actual drug levels in patients, compare them to target ranges, and adjust dosages accordingly. The feedback loop created by this assay enables individualized dosing that maintains treatment efficacy while minimizing toxicity by avoiding both under-dosing and excessive dosing, directly addressing the pharmacokinetic variability issue
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies allow for accurate monitoring of imatinib levels in patients, facilitating individualized drug dosing and minimizing toxicity, thereby enhancing treatment efficacy and compliance by providing a specific and sensitive immunoassay adapted for standard laboratory equipment.
Implementation Method 1
a new class of antibodies have been produced which are substantially selectively reactive to imatinib and its pharmacologically active salts so as to selectively bind to imatinib and its pharmacologically active salts without any substantial cross reactivity to the its pharmacologically active imatinib metabolite, N-desmethyl imatinib
Data Source
AI summary
Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids.